BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut 2018;67:1328-41. [PMID: 29275358 DOI: 10.1136/gutjnl-2017-315402] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Dun S, Gao L. Tanshinone I attenuates proliferation and chemoresistance of cervical cancer in a KRAS-dependent manner. J Biochem Mol Toxicol 2019;33:e22267. [PMID: 30506648 DOI: 10.1002/jbt.22267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li Y, Hu L, Xu C. Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer. Curr Opin Oncol 2022;34:66-76. [PMID: 34690284 DOI: 10.1097/CCO.0000000000000808] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Xu W, Deng B, Lin P, Liu C, Li B, Huang Q, Zhou H, Yang J, Qu L. Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells. Sci China Life Sci 2020;63:529-42. [DOI: 10.1007/s11427-019-9580-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
4 Liang Y, Liang Q, Qiao L, Xiao F. MicroRNAs Modulate Drug Resistance-Related Mechanisms in Hepatocellular Carcinoma. Front Oncol 2020;10:920. [PMID: 32695666 DOI: 10.3389/fonc.2020.00920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 2020;51:102610. [PMID: 31918403 DOI: 10.1016/j.ebiom.2019.102610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
6 Gaza A, Fritz V, Malek L, Wormser L, Treiber N, Danner J, Kremer AE, Thasler WE, Siebler J, Meister G, Neurath MF, Hellerbrand C, Bosserhoff AK, Dietrich P. Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11. Neoplasia 2021;23:502-14. [PMID: 33901943 DOI: 10.1016/j.neo.2021.04.001] [Reference Citation Analysis]
7 Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging (Albany NY) 2020;12:22975-3003. [PMID: 33203790 DOI: 10.18632/aging.104028] [Reference Citation Analysis]
8 Lei H, Wang G, Zhang J, Han Q. Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity. Oncol Rep 2018;40:3447-57. [PMID: 30272318 DOI: 10.3892/or.2018.6740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zeng Z, Lu Q, Liu Y, Zhao J, Zhang Q, Hu L, Shi Z, Tu Y, Xiao Z, Xu Q, Huang D. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:641522. [PMID: 34307125 DOI: 10.3389/fonc.2021.641522] [Reference Citation Analysis]
10 Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87. [PMID: 32532960 DOI: 10.1038/s41392-020-0187-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
11 Liu N, Steer CJ, Song G. MicroRNA-206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c-Myc mice. Hepatology 2021. [PMID: 34606648 DOI: 10.1002/hep.32182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gao L, Morine Y, Yamada S, Saito Y, Ikemoto T, Tokuda K, Takasu C, Miyazaki K, Shimada M. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells. PLoS One 2021;16:e0256755. [PMID: 34473785 DOI: 10.1371/journal.pone.0256755] [Reference Citation Analysis]
13 Wu B, Li A, Zhang Y, Liu X, Zhou S, Gan H, Cai S, Liang Y, Tang X. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles. Expert Opinion on Drug Delivery 2020;17:573-87. [DOI: 10.1080/17425247.2020.1730809] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mahli A, Seitz T, Beckröge T, Freese K, Thasler WE, Benkert M, Dietrich P, Weiskirchen R, Bosserhoff A, Hellerbrand C. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. Cells 2019;8:E457. [PMID: 31096638 DOI: 10.3390/cells8050457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lu J, Xie Z, Xiao Z, Zhu D. The expression and function of miR-622 in a variety of tumors. Biomed Pharmacother 2021;146:112544. [PMID: 34929578 DOI: 10.1016/j.biopha.2021.112544] [Reference Citation Analysis]
16 Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M, McCubrey JA. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets 2019;23:915-29. [PMID: 31657972 DOI: 10.1080/14728222.2019.1685501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
17 Li Y, He X, Zhang X, Xu Y, Wu Y, Xu X. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma. Life Sci 2021;265:118799. [PMID: 33220285 DOI: 10.1016/j.lfs.2020.118799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Shen Z, Zhang C, Qu L, Lu C, Xiao M, Ni R, Liu J. MKP-4 suppresses hepatocarcinogenesis by targeting ERK1/2 pathway. Cancer Cell Int 2019;19:61. [PMID: 30923463 DOI: 10.1186/s12935-019-0776-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Dietrich P, Hellerbrand C, Bosserhoff A. The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression. Cancers (Basel) 2019;11:E398. [PMID: 30901922 DOI: 10.3390/cancers11030398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
20 Chien YC, Chen JN, Chen YH, Chou RH, Lee HC, Yu YL. Epigenetic Silencing of miR-9 Promotes Migration and Invasion by EZH2 in Glioblastoma Cells. Cancers (Basel) 2020;12:E1781. [PMID: 32635336 DOI: 10.3390/cancers12071781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Linck-Paulus L, Hellerbrand C, Bosserhoff AK, Dietrich P. Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. Cells 2020;9:E114. [PMID: 31906510 DOI: 10.3390/cells9010114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Dietrich P, Wormser L, Fritz V, Seitz T, De Maria M, Schambony A, Kremer AE, Günther C, Itzel T, Thasler WE, Teufel A, Trebicka J, Hartmann A, Neurath MF, von Hörsten S, Bosserhoff AK, Hellerbrand C. Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. J Clin Invest 2020;130:2509-26. [PMID: 31999643 DOI: 10.1172/JCI131919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
23 Bantel H, Canbay A. Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication. Gut 2018;67:1206-7. [PMID: 29353250 DOI: 10.1136/gutjnl-2017-315630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
24 Najafi M, Ahmadi A, Mortezaee K. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review. Cell Biol Int. 2019;43:1206-1222. [PMID: 31136035 DOI: 10.1002/cbin.11187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
25 Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut 2020;69:748-63. [PMID: 32034004 DOI: 10.1136/gutjnl-2019-318279] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 37.0] [Reference Citation Analysis]
26 Zhao W, Ma B, Tian Z, Han H, Tang J, Dong B, An G, Cao B, Wang B. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance. Br J Cancer 2021;124:1237-48. [PMID: 33473171 DOI: 10.1038/s41416-020-01240-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Manna D, Sarkar D. Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1243. [PMID: 32429062 DOI: 10.3390/cancers12051243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Lett. 2019;460:1-9. [PMID: 31207320 DOI: 10.1016/j.canlet.2019.114428] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 16.7] [Reference Citation Analysis]
29 Fritz V, Malek L, Gaza A, Wormser L, Appel M, Kremer AE, Thasler WE, Siebler J, Neurath MF, Hellerbrand C, Bosserhoff AK, Dietrich P. Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1183. [PMID: 33803354 DOI: 10.3390/cancers13051183] [Reference Citation Analysis]
30 Chen X, Tan W, Li W, Li W, Zhu S, Zhong J, Shang C, Chen Y. miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression. J Cancer 2019;10:2745-53. [PMID: 31258782 DOI: 10.7150/jca.31804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
31 Liu XX, Yang YE, Liu X, Zhang MY, Li R, Yin YH, Qu YQ. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma. J Transl Med 2019;17:50. [PMID: 30777071 DOI: 10.1186/s12967-019-1800-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
32 Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Bosserhoff AK. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Neoplasia 2019;21:257-68. [PMID: 30685691 DOI: 10.1016/j.neo.2018.11.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
33 Roncarati R, Lupini L, Shankaraiah RC, Negrini M. The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer. Front Oncol 2019;9:988. [PMID: 31612113 DOI: 10.3389/fonc.2019.00988] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
34 Zhang X, Xu X, Ge G, Zang X, Shao M, Zou S, Zhang Y, Mao Z, Zhang J, Mao F, Qian H, Xu W. miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2. Oncol Rep 2019;41:1638-48. [PMID: 30592286 DOI: 10.3892/or.2018.6948] [Cited by in Crossref: 12] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
35 Feuerer L, Lamm S, Henz I, Kappelmann-Fenzl M, Haferkamp S, Meierjohann S, Hellerbrand C, Kuphal S, Bosserhoff AK. Role of melanoma inhibitory activity in melanocyte senescence. Pigment Cell Melanoma Res 2019;32:777-91. [PMID: 31172672 DOI: 10.1111/pcmr.12801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
36 Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL, De Toni EN. The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Discov 2019;5:86. [PMID: 30962952 DOI: 10.1038/s41420-019-0165-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
37 Lai Y, Feng B, Abudoureyimu M, Zhi Y, Zhou H, Wang T, Chu X, Chen P, Wang R. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. Front Oncol 2019;9:1156. [PMID: 31750247 DOI: 10.3389/fonc.2019.01156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
38 Targhazeh N, Yousefi B, Asghari S, Mohammadnejhad R, Mansouri P, Valizadeh A. MiR-622 acts as a tumor suppressor to induce cell apoptosis and inhibit metastasis in human prostate cancer. Andrologia 2021;:e14174. [PMID: 34231241 DOI: 10.1111/and.14174] [Reference Citation Analysis]
39 Seitz T, Freese K, Dietrich P, Thasler WE, Bosserhoff A, Hellerbrand C. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. Sci Rep 2020;10:4546. [PMID: 32161315 DOI: 10.1038/s41598-020-61510-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
40 Wang D, Hu X, Long G, Xiao L, Wang ZM, Zhou LD. The clinical value of total plasma cell-free DNA in hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med 2019;7:650. [PMID: 31930051 DOI: 10.21037/atm.2019.10.78] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
41 Pommer M, Kuphal S, Bosserhoff AK. Amphiregulin Regulates Melanocytic Senescence. Cells 2021;10:326. [PMID: 33562468 DOI: 10.3390/cells10020326] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Shan C, Chen X, Cai H, Hao X, Li J, Zhang Y, Gao J, Zhou Z, Li X, Liu C, Li P, Wang K. The Emerging Roles of Autophagy-Related MicroRNAs in Cancer. Int J Biol Sci 2021;17:134-50. [PMID: 33390839 DOI: 10.7150/ijbs.50773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 de Jel MM, Schott M, Lamm S, Neuhuber W, Kuphal S, Bosserhoff AK. Loss of CYLD accelerates melanoma development and progression in the Tg(Grm1) melanoma mouse model. Oncogenesis 2019;8:56. [PMID: 31591386 DOI: 10.1038/s41389-019-0169-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
44 Dai J, Huang Q, Niu K, Wang B, Li Y, Dai C, Chen Z, Tao K, Dai J. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. Cancer Med 2018;7:5691-703. [PMID: 30311444 DOI: 10.1002/cam4.1826] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
45 Wang W, Liu Q, Zhang T, Chen L, Li S, Xu S. Glyphosate induces lymphocyte cell dysfunction and apoptosis via regulation of miR-203 targeting of PIK3R1 in common carp (Cyprinus carpio L.). Fish Shellfish Immunol 2020;101:51-7. [PMID: 32217141 DOI: 10.1016/j.fsi.2020.03.047] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
46 Freese K, Seitz T, Dietrich P, Lee SML, Thasler WE, Bosserhoff A, Hellerbrand C. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. Cancers (Basel) 2019;11:E1587. [PMID: 31635225 DOI: 10.3390/cancers11101587] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
47 Ma Q, Xu Q, Zhao J, Zhang W, Wang Q, Fang J, Lu Z, Liu J, Ma L. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. Cancer Lett 2021;520:243-54. [PMID: 34339801 DOI: 10.1016/j.canlet.2021.07.049] [Reference Citation Analysis]
48 Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK. MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma. Pigment Cell Melanoma Res 2018;31:614-29. [PMID: 29495114 DOI: 10.1111/pcmr.12698] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
49 Vigneron N, Vernon M, Meryet-Figuière M, Lambert B, Briand M, Louis MH, Krieger S, Joly F, Lheureux S, Blanc-Fournier C, Gauduchon P, Poulain L, Denoyelle C. Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma. Clin Chem 2020;66:352-62. [PMID: 32040573 DOI: 10.1093/clinchem/hvz013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
50 Sun G, Su G, Liu F, Han W. NRAS Contributes to Retinoblastoma Progression Through SNHG16/miR-183-5p/NRAS Regulatory Network. Onco Targets Ther 2019;12:10703-15. [PMID: 31827328 DOI: 10.2147/OTT.S232470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]